Добавил:
kiopkiopkiop18@yandex.ru t.me/Prokururor I Вовсе не секретарь, но почту проверяю Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз: Предмет: Файл:
Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_917_Библиотеки_им_академика_М_И_Перельмана.pdf
Скачиваний:
0
Добавлен:
31.08.2026
Размер:
32 Мб
Скачать
22 Principles ofRectal Cancer Management: Preoperative Staging, Neoadjuvant…
centers, a sizable proportion of patients (as high as 17%) do not complete postop­erative chemotherapy [48].
Optimal duration of adjuvant chemotherapy after proctectomy also remains undetermined. Based on extrapolation from the MOSAIC trial, which led to the adoption of 6months of FOLFOX as the standard of care for locally advanced colon cancer, the National Comprehensive Cancer Network guidelines currently recom­mend a total of 6 months of chemotherapy for rectal cancer. Accounting for the 2months of uoropyrimidine chemotherapy administered concurrently with radia­tion prior to proctectomy, this translates to approximately 4 months of adjuvant FOLFOX.
347

Total Neoadjuvant Therapy

In the modern era, patients with rectal cancer more commonly experience distant metastatic disease than local recurrence, with more than 25% of stage II and III rectal cancers causing metastatic disease. Although neoadjuvant chemoradiation has been shown to decrease the incidence of local recurrence, overall survival and risk of distant metastases are not impacted by chemoradiation. In an effort to pre­vent distant disease and increase long-term survival, the early introduction of both chemotherapy and chemoradiation prior to surgery is being investigated. Theoretical benets include earlier protection against dissemination of micrometastatic disease, delivery of chemotherapy to the primary tumor with undisrupted vasculature, tumor downstaging, less toxicity, and better adherence to prescribed treatment.
The novel concept of total neoadjuvant therapy (TNT), in which chemoradiation and chemotherapy are administered prior to surgery, has been shown to be safe and effective [49]. A recent retrospective study conducted at Memorial Sloan Kettering analyzed records of patients treated between 2009 and 2015. Of the 811 patients identied, 320 received chemoradiation with planned adjuvant chemotherapy, and 308 received TNT (induction FOLFOX-based chemotherapy followed by chemora­diation). Patients in the TNT cohort received greater percentages of the planned chemotherapy than those in the chemoradiation with planned adjuvant chemother­apy cohort. The rate of complete response, including both pathologic complete response in patients who underwent surgery and sustained clinical complete response for at least 12months posttreatment in patients who did not undergo sur­gery, was 36% in the TNT cohort compared with 21% in the chemoradiation with planned adjuvant chemotherapy cohort. These ndings provide additional support for TNT as a viable treatment strategy for rectal cancer. TNT may facilitate nonop­erative treatment strategies aimed at organ preservation.

Nonoperative Management

Chemoradiation can lead to pCR, and selected patients with such response can potentially avoid surgery. This nonoperative management strategy is referred to as the watch-and-wait approach. Avoiding surgery can potentially lead to better
348
E. Pappou and M. R. Weiser
functional outcomes and better quality of life. The largest systematic study on this approach was conducted in Brazil [50]. Of 361 patients treated with chemoradia­tion, 122 attained clinical complete response, and 99 (27%) had sustained complete regression for at least 1year. Clinical complete response was dened as absence of residual mass or ulcer on clinical evaluation and endoscopy, as well as no residual tumor on imaging studies. Of the 99 patients with sustained complete regression, only 5% developed endoluminal recurrences, none developed pelvic regional recur­rence, and 8% developed metastatic disease. Of the 5 patients who developed endo­luminal recurrences, 3 underwent salvage APR or low anterior resection, while 2 declined radical surgery and underwent local excision or brachytherapy. The 5-year rates of overall and disease-free survival were 93% and 85%, respectively. Retrospective studies conducted in the United Kingdom, the Netherlands, and the United States reported similar ndings, suggesting that watch-and-wait can be a reasonable option in carefully selected and closely followed patients [51, 52]. A number of multi-institutional prospective observational studies and Phase II trials are currently testing the feasibility of incorporating nonoperative management in multimodal treatment of rectal cancer, but at the present time, nonoperative man­agement should be considered experimental and should ideally take place in the setting of a clinical trial.

Conclusion

Decades of basic science and clinical research have resulted in a multitude of treat­ment options for patients with rectal cancer, providing dramatic improvement inlocal control and patient survival. Multidisciplinary management of rectal can­cer– involving surgical, radiation, and medical oncologists; pathologists; and radi­ologists – has been shown to improve clinical decision-making and clinical outcomes. The ability to differentiate levels of risk for tumor recurrence and sur­vival prognoses based on baseline tumor characteristics and response to therapy will enable future tailoring of treatment to disease biology to reduce morbidity and improve outcomes.
Acknowledgments The authors thank Arthur Gelmis, editor in the Colorectal Surgery Service at
the Memorial Sloan Kettering Cancer Center, for his assistance in editing this chapter.

References

1. Extramural depth of tumor invasion at thin-section MR in patients with rectal cancer: results
of the MERCURY study. Radiology. 2007;243(1):132–9.
2. Glynne-Jones R, Wyrwicz L, Tiret E, Brown G, Rodel C, Cervantes A, etal. Rectal cancer:
ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(suppl_4):iv22–40.
22 Principles ofRectal Cancer Management: Preoperative Staging, Neoadjuvant…
3. Callender GG, Das P, Rodriguez-Bigas MA, Skibber JM, Crane CH, Krishnan S, etal. Local
excision after preoperative chemoradiation results in an equivalent outcome to total mesorectal excision in selected patients with T3 rectal cancer. Ann Surg Oncol. 2010;17(2):441–7.
4. Shin YS, Yoon YS, Lim SB, Yu CS, Kim TW, Chang HM, et al. Preoperative chemora-
diotherapy followed by local excision in clinical T2N0 rectal cancer. Radiat Oncol J. 2016;34(3):177–85.
5. Nair RM, Siegel EM, Chen DT, Fulp WJ, Yeatman TJ, Malafa MP, etal. Long-term results of
transanal excision after neoadjuvant chemoradiation for T2 and T3 adenocarcinomas of the rectum. J Gastrointest Surg. 2008;12(10):1797–805; discussion 805–6.
6. Garcia-Aguilar J, Renfro LA, Chow OS, Shi Q, Carrero XW, Lynn PB, etal. Organ preserva-
tion for clinical T2N0 distal rectal cancer using neoadjuvant chemoradiotherapy and local excision (ACOSOG Z6041): results of an open-label, single-arm, multi-institutional, phase 2 trial. Lancet Oncol. 2015;16(15):1537–46.
7. Maslekar S, Sharma A, Macdonald A, Gunn J, Monson JR, Hartley JE.Mesorectal grades predict
recurrences after curative resection for rectal cancer. Dis Colon Rectum. 2007;50(2):168–75.
8. Nagtegaal ID, van de Velde CJ, van der Worp E, Kapiteijn E, Quirke P, van Krieken
JH.Macroscopic evaluation of rectal cancer resection specimen: clinical signicance of the pathologist in quality control. J Clin Oncol. 2002;20(7):1729–34.
9. Rullier E, Denost Q, Vendrely V, Rullier A, Laurent C.Low rectal cancer: classication and
standardization of surgery. Dis Colon Rectum. 2013;56(5):560–7.
10. Bonjer HJ, Deijen CL, Haglind EA.Randomized trial of laparoscopic versus open surgery for
rectal cancer. N Engl J Med. 2015;373(2):194.
11. Stevenson ARL, Solomon MJ, Brown CSB, Lumley JW, Hewett P, Clouston AD, etal. Disease-
free survival and local recurrence after laparoscopic-assisted resection or open resection for rectal cancer: the Australasian laparoscopic cancer of the rectum randomized clinical trial. Ann Surg. 2019;269(4):596–602.
12. Jayne D, Pigazzi A, Marshall H, Croft J, Corrigan N, Copeland J, etal. Effect of robotic-
assisted vs conventional laparoscopic surgery on risk of conversion to open laparotomy among patients undergoing resection for rectal cancer: the ROLARR randomized clinical trial. JAMA. 2017;318(16):1569–80.
13. Penna M, Hompes R, Arnold S, Wynn G, Austin R, Warusavitarne J, et al. Transanal
total mesorectal excision: international registry results of the rst 720 cases. Ann Surg. 2017;266(1):111–7.
14. Lee GC, Sylla P.Shifting paradigms in minimally invasive surgery: applications of transanal
natural orice transluminal endoscopic surgery in colorectal surgery. Clin Colon Rectal Surg. 2015;28(3):181–93.
15. Dietz DW.Multidisciplinary management of rectal cancer: the OSTRICH.J Gastrointest Surg.
2013;17(10):1863–8.
16. Monson JRT, Dietz DW, Boughey JC, You YN.Improving rectal cancer outcomes through
advocacy, education, and research: the OSTRiCh Consortium and the new NAPRC.Bull Am Coll Surg. 2016;101(11):45–6.
17. Karagkounis G, Stocchi L, Lavery IC, Liska D, Gorgun E, Veniero J, etal. Multidisciplinary
conference and clinical management of rectal cancer. J Am Coll Surg. 2018;226(5):874–80.
18. Khani MH, Smedh K. Centralization of rectal cancer surgery improves long-term survival.
Colorectal Dis. 2010;12(9):874–9.
19. Bulow S, Harling H, Iversen LH, Ladelund S. Improved survival after rectal cancer in
Denmark. Colorectal Dis. 2010;12(7 Online):e37–42.
20. Rombeau JL, Collins JP, Turnbull RB Jr. Left-sided colectomy with retroileal colorectal anas-
tomosis. Arch Surg. 1978;113(8):1004–5.
21. MacFarlane JK, Ryall RD, Heald RJ. Mesorectal excision for rectal cancer. Lancet.
1993;341(8843):457–60.
22. Enker WE, Thaler HT, Cranor ML, Polyak T.Total mesorectal excision in the operative treat-
ment of carcinoma of the rectum. J Am Coll Surg. 1995;181(4):335–46.
349
350
23. Arbman G, Nilsson E, Hallbook O, Sjodahl R.Local recurrence following total mesorectal
excision for rectal cancer. Br J Surg. 1996;83(3):375–9.
24. Bjerkeset T, Edna TH.Rectal cancer: the inuence of type of operation on local recurrence and
survival. Eur J Surg. 1996;162(8):643–8.
25. Heald RJ, Moran BJ, Ryall RD, Sexton R, MacFarlane JK. Rectal cancer: the Basingstoke
experience of total mesorectal excision, 1978-1997. Arch Surg. 1998;133(8):894–9.
26. Wibe A, Moller B, Norstein J, Carlsen E, Wiig JN, Heald RJ, etal. A national strategic change
in treatment policy for rectal cancer– implementation of total mesorectal excision as routine treatment in Norway. A national audit. Dis Colon Rectum. 2002;45(7):857–66.
27. Kapiteijn E, Putter H, van de Velde CJ.Impact of the introduction and training of total meso-
rectal excision on recurrence and survival in rectal cancer in the Netherlands. Br J Surg. 2002;89(9):1142–9.
28. Martling AL, Holm T, Rutqvist LE, Moran BJ, Heald RJ, Cedemark B. Effect of a surgi-
cal training programme on outcome of rectal cancer in the County of Stockholm. Stockholm Colorectal Cancer Study Group, Basingstoke Bowel Cancer Research Project. Lancet. 2000;356(9224):93–6.
29. Camilleri-Brennan J, Steele RJ. Quality of life after treatment for rectal cancer. Br J Surg.
1998;85(8):1036–43.
30. Enker WE.Potency, cure, and local control in the operative treatment of rectal cancer. Arch
Surg. 1992;127(12):1396–401; discussion 402.
31. Havenga K, Enker WE, McDermott K, Cohen AM, Minsky BD, Guillem J.Male and female
sexual and urinary function after total mesorectal excision with autonomic nerve preservation for carcinoma of the rectum. J Am Coll Surg. 1996;182(6):495–502.
32. Shirouzu K, Ogata Y, Araki Y. Oncologic and functional results of total mesorectal exci-
sion and autonomic nerve-preserving operation for advanced lower rectal cancer. Dis Colon Rectum. 2004;47(9):1442–7.
33. Sauer R, Becker H, Hohenberger W, Rodel C, Wittekind C, Fietkau R, etal. Preoperative ver-
sus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004;351(17):1731–40.
34. Sauer R, Liersch T, Merkel S, Fietkau R, Hohenberger W, Hess C, etal. Preoperative versus
postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol. 2012;30(16):1926–33.
35. Roh MS, Colangelo LH, O'Connell MJ, Yothers G, Deutsch M, Allegra CJ, etal. Preoperative
multimodality therapy improves disease-free survival in patients with carcinoma of the rec­tum: NSABP R-03. J Clin Oncol. 2009;27(31):5124–30.
36. Bosset JF, Calais G, Mineur L, Maingon P, Radosevic-Jelic L, Daban A, et al. Enhanced
tumorocidal effect of chemotherapy with preoperative radiotherapy for rectal cancer: prelimi­nary results--EORTC 22921. J Clin Oncol. 2005;23(24):5620–7.
37. Bosset JF, Collette L, Calais G, Mineur L, Maingon P, Radosevic-Jelic L, etal. Chemotherapy
with preoperative radiotherapy in rectal cancer. N Engl J Med. 2006;355(11):1114–23.
38. Gerard JP, Conroy T, Bonnetain F, Bouche O, Chapet O, Closon-Dejardin MT, et al.
Preoperative radiotherapy with or without concurrent uorouracil and leucovorin in T3-4 rec­tal cancers: results of FFCD 9203. J Clin Oncol. 2006;24(28):4620–5.
39. Ngan SY, Burmeister B, Fisher RJ, Solomon M, Goldstein D, Joseph D, et al. Randomized
trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group trial
01.04. J Clin Oncol. 2012;30(31):3827–33.
40. Erlandsson J, Holm T, Pettersson D, Berglund A, Cedermark B, Radu C, etal. Optimal frac-
tionation of preoperative radiotherapy and timing to surgery for rectal cancer (Stockholm III): a multicentre, randomised, non-blinded, phase 3, non-inferiority trial. Lancet Oncol. 2017;18(3):336–46.
41. Mirnezami R, Chang GJ, Das P, Chandrakumaran K, Tekkis P, Darzi A, et al. Intraoperative
radiotherapy in colorectal cancer: systematic review and meta-analysis of techniques, long­term outcomes, and complications. Surg Oncol. 2013;22(1):22–35.
E. Pappou and M. R. Weiser
22 Principles ofRectal Cancer Management: Preoperative Staging, Neoadjuvant…
42. Taylor FG, Quirke P, Heald RJ, Moran B, Blomqvist L, Swift I, et al. Preoperative high-
resolution magnetic resonance imaging can identify good prognosis stage I, II, and III rectal cancer best managed by surgery alone: a prospective, multicenter, European study. Ann Surg. 2011;253(4):711–9.
43. Schrag D, Weiser MR, Goodman KA, Gonen M, Hollywood E, Cercek A, etal. Neoadjuvant
chemotherapy without routine use of radiation therapy for patients with locally advanced rectal cancer: a pilot trial. J Clin Oncol. 2014;32(6):513–8.
44. Weiser MR, Fichera A, Schrag D, Boughey JC, You YN.Progress in the PROSPECT trial:
precision treatment for rectal cancer? Bull Am Coll Surg. 2015;100(4):51–2.
45. Petersen SH, Harling H, Kirkeby LT, Wille-Jorgensen P, Mocellin S. Postoperative adju-
vant chemotherapy in rectal cancer operated for cure. Cochrane Database Syst Rev. 2012;(3):CD004078.
46. Biagi JJ, Raphael MJ, Mackillop WJ, Kong W, King WD, Booth CM.Association between
time to initiation of adjuvant chemotherapy and survival in colorectal cancer: a systematic review and meta-analysis. JAMA. 2011;305(22):2335–42.
47. Haynes AB, You YN, Hu CY, Eng C, Kopetz ES, Rodriguez-Bigas MA, etal. Postoperative che-
motherapy use after neoadjuvant chemoradiotherapy for rectal cancer: Analysis of Surveillance, Epidemiology, and End Results-Medicare data, 1998-2007. Cancer. 2014;120(8):1162–70.
48. Khrizman P, Niland JC, ter Veer A, Milne D, Bullard Dunn K, Carson WE 3rd, et al.
Postoperative adjuvant chemotherapy use in patients with stage II/III rectal cancer treated with neoadjuvant therapy: a national comprehensive cancer network analysis. J Clin Oncol. 2013;31(1):30–8.
49. Cercek A, Roxburgh CSD, Strombom P, Smith JJ, Temple LKF, Nash GM, etal. Adoption of
total neoadjuvant therapy for locally advanced rectal cancer. JAMA Oncol. 2018;4(6):e180071.
50. Habr-Gama A, Perez RO, Proscurshim I, Campos FG, Nadalin W, Kiss D, et al. Patterns of
failure and survival for nonoperative treatment of stage c0 distal rectal cancer following neo­adjuvant chemoradiation therapy. J Gastrointest Surg. 2006;10(10):1319–28; discussion 28–9.
51. Smith JJ, Strombom P, Chow OS, Roxburgh CS, Lynn P, Eaton A, etal. Assessment of a
watch-and-wait strategy for rectal cancer in patients with a complete response after neoadju­vant therapy. JAMA Oncol. 2019;5:e185896.
52. Renehan AG, Malcomson L, Emsley R, Gollins S, Maw A, Myint AS, et al. Watch-and-
wait approach versus surgical resection after chemoradiotherapy for patients with rectal cancer (the OnCoRe project): a propensity-score matched cohort analysis. Lancet Oncol. 2016;17(2):174–83.
53. Valinluck Lao V, Fichera A.Endorectal ultrasound. In: Chang GJ, editor. Rectal cancer: mod-
ern approaches to treatment. Cham: Springer International Publishing; 2018.
54. Ferrari L, Fichera A.Neoadjuvant chemoradiation therapy and pathological complete response
in rectal cancer. Gastroenterol Rep (Oxf). 2015;3(4):277–88.
55. Hakiman H, Boostrom S, Fleshman J. Total mesorectal excision with autonomic nerve pres-
ervation: “optimized surgery”. In: Long WE, Reddy V, Audisio RA, editors. Modern manage­ment of cancer of the rectum. 2nd ed. Cham: Springer International Publishing; 2015.
351
Laparoscopic Low Anterior Resection forRectal Cancer: TME Planes
23
andSurgery oftheUpper andMid-Rectum
EricM.Haas andAmandaV.Hayman
Introduction andRationale
Laparoscopic low anterior resection for rectal cancer is one of the more challenging minimally invasive colorectal procedures to master. The conned and narrow spaces of the pelvis often limit visualization, exposure, and access. Additionally, it is imperative to maintain proper planes of dissection to achieve a sound oncologic resection. Straying from the embryologic planes may result in a eld obscured with nuisance bleeding and injury to critical structures. It is therefore essential to approach each case in a stepwise fashion with a clear understanding of the anatomi­cal considerations as well as the precise location of the tumor.
The benets of laparoscopy are well known and include less pain, earlier return of bowel function, shorter length of stay, and fewer wound complications. With modern techniques and newer technologies, there is rarely a case that cannot be approached using laparoscopic technique. More challenging patients including those with multiple medical morbidities, extreme obesity, or prior open abdominal procedures, often tend to benet the most. Therefore, our initial approach is to gain access laparoscopically and assess if all or parts of the procedure can be accom­plished in this fashion to limit the morbidity of a large incision.
In the absence of locally advanced disease or a threatened circumferential resection margin (CRM), upper rectal tumors, and select mid-rectal tumors, are treated like colon cancers via upfront surgical resection, avoiding the morbidity of
E. M. Haas (*) Division of Colon and Rectal Surgery, Houston Methodist Hospital, Department of Surgery, Houston, TX, USA e-mail: ehaasmd@houstoncolon.com
A. V. Hayman The Oregon Clinic, Division of Gastrointestinal and Minimally Invasive Surgery, Oregon Health and Science University, Department of Surgery, Portland, OR, USA e-mail: ahayman@orclinic.com
© Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) 2020 P. Sylla et al. (eds.), The SAGES Manual of Colorectal Surgery,
https://doi.org/10.1007/978-3-030-24812-3_23
353
354
E. M. Haas and A. V. Hayman
neoadjuvant chemoradiotherapy. Standard oncologic vascular pedicle ligation of the inferior mesenteric artery (IMA) is performed with regional lymphadenectomy and is referred to as tumor-specic mesorectal excision (TSME).
However, the delineation between the upper and mid-rectum and the lower rec­tum can be controversial. Intraoperatively, the top of the rectum can be identied by where the taenias play and the epiploic appendages peter out. Obviously, this is not applicable preoperatively. If the tumor is large enough, it can be detected by CT or MRI, thus providing reliable anatomic landmarks, such as distance from the values of Houston or the sacral promontory. An approximation of the location of the ante­rior reection, and thus the delineation between the sigmoid colon and the rectum, is a line drawn between the top of the sacral promontory and the bottom of the pubic symphysis. However, in many cases, the exact intraluminal borders of the tumor are not easily seen on cross-sectional imaging. Therefore, the most important initial step for the surgeon in the workup for a newly diagnosed rectal cancer is rigid proc­toscopy. This is a much more reliable assessment of “true” distance from the anal verge than exible endoscopy, which should not be solely relied upon for surgical planning. Marking the tumor distally via tattoo may also aid in identication, intra­operatively, especially if CO
colonoscopy is not readily available. The surgeon
2
should also be aware, however, that occasionally tattoo marks can obscure the ana­tomical visualization during the minimally invasive procedure. Proctoscopy also allows the surgeon to determine in which quadrant(s) the tumor is located, which has implication during resection about what structures would be potentially threat­ened (i.e., an anterior-based tumor may closely abut or involve the prostate or vagina). Further, patient habitus may inuence surgical approach. An obese, muscu­lar man may have a longer anal canal, and thus the tumor may be closer to the top of the anal sphincters (aka the “anorectal ring”) making a laparoscopic approach more difcult. Proctoscopy also allows for serial assessment of response to neoad­juvant treatment, as well as to detect recurrence during surveillance.
This chapter addresses rectal cancer involving the upper and mid-rectum and, despite many similarities, leaves out the most distal rectal cancer. For the purposes of this chapter, we dene the lower rectum as the distal 5cm, the mid-rectum from 6–11 cm, and the upper rectum as above 11 cm (or above the second valve of Houston). Most studies on rectal cancer dene the top of the rectum as 15cm from the anal verge [1]. There are several important distinctions between upper and mid­dle rectal cancers. Upper rectal cancers are typically managed with upfront surgical resection. An adequate distal resection margin and mesorectal excision can be read­ily achieved with a laparoscopic technique. It is important to understand the ana­tomical concepts of a tumor-specic mesorectal excision (TSME). To achieve a TSME, a minimum of 2cm distal margin on the rectum is required, as well as a 5cm distal margin of the mesorectum [2, 3]. Care is taken to avoid the tendency to cone inward and divide across the mesentery within the required margins.
Mid-rectal cancers are more often subject to neoadjuvant chemoradiation ther­apy if determined to be locally advanced (Stage II or III disease, i.e., T3 and/or node-positive disease). TSME is not typically feasible for most tumors of the mid­rectum due to the constraints of the narrow pelvis and bulky mesentery of the mid­rectum. In most cases, a total mesorectal excision (TME) with low pelvic colorectal anastomosis is the most technically feasible approach to surgical resection of
23 Laparoscopic Low Anterior Resection forRectal Cancer: TME Planes andSurgery…
355
mid-rectal cancers. Minimally invasive techniques become much more cumber­some and difcult in these cases and are addressed in the chapters on principles of rectal cancer and robotic low anterior resection (Chaps. 22 and 24).
Indications andContraindications
A laparoscopic TSME can be considered in many, but not all, patients. Patients with certain comorbidities, such as extreme obesity or severe pulmonary dysfunction, may not tolerate prolonged Trendelenburg positioning and/or insufation, as can be seen intraoperatively by high airway pressures or CO choose to partially mitigate these concerns by using lower insufation pressures (such as 10–12mmHg instead of the standard 15), but this may still be insufcient. Another option is to perform only the splenic exure mobilization laparoscopically, which typically uses reverse Trendelenburg positioning, and then completing the pelvic dissection via a Pfannenstiel or lower midline incision. In addition to these patient factors, there are also tumor characteristics that may make a laparoscopic approach more challenging: a large, bulky tumor or presence of a colonic stent can prevent adequate retraction and visualization. Occasionally, adding another assist port can help, but not always. Additionally, presence of a perforated tumor or involved radial margins may require dissection outside the standard TME planes. This can result in a bloodier eld, impeding laparoscopic visualization. Further, ensuring a negative radial margin in the setting of extreme brosis, such as after an intense radiation reaction, reoperative surgery, or previous perforation, can be dif­cult without direct tactile feedback. However, except for patient intolerance of laparoscopy, the cases listed above are relative contraindications and highly depend on the skill of the individual surgeon.
If the surgeon is able to maintain the principles of adhering to the avascular mesorectal planes of dissection, ensure proper radial and distal margins, ensure proper lymph node harvest to the base of the inferior mesenteric artery (IMA), and ensure an intact specimen, the laparoscopic approach is appropriate.
retention. The surgeon can
2
Principles andQuality Benchmarks
Ultimately, regardless of the operative approach chosen by the surgeon, a quality oncologic outcome should never be sacriced. The same quality oncologic bench­marks for TME apply to TSME.As per the National Comprehensive Cancer Network (NCCN) guidelines and National Accreditation Program in Rectal Cancer (NAPRC) standards, an adequate lymphadenectomy is a harvest of a minimum of 12 lymph nodes. The commonly accepted distances to be considered an adequate margin are as follows: radial (>1mm), distal (2cm), and mesenteric (5cm) [3]. Although the exact factors that predispose for low anterior resection syndrome (bowel dysfunction char­acterized by stool clustering, increased frequency, urgency, or incomplete emptying) are multifactorial, taking care to preserve the paired hypogastric nerves that run along the back of the rectum distal to the sacral promontory may mitigate this risk. Because of this risk, it is important to preoperatively assess the patient’s bowel
356
E. M. Haas and A. V. Hayman
function and at all future postoperative appointments. There are many validated questionnaires that assess patient-reported outcomes regarding bowel function, including the FIQOL (fecal incontinence quality of life), the MSKCC bowel function instrument, or the EORTC QOL questionnaire for colorectal cancer surgery (QLQ-CR38). Sexual function may also be impaired postoperatively, likely due to injury to the nervi erigentes that course horizontally near the lateral rectal stalks.
Although the surgeon will not be performing a complete mesorectal excision, the same avascular presacral plane needs to be maintained while keeping the fascia propria of the mesorectum intact. Similar to the surgical principles of a TME, it is essential to not “cone in” on the mesentery when planning where to perform the rectal transection. It is also essential to harvest the lymph nodes at the base of the IMA and maintain the dissection into the retroperitoneal planes along the superior rectal artery leading to the mesorectal dissection.
Preoperative Planning, Patient Workup, andOptimization
The initial workup includes serum CEA level and CT scan of the chest, abdomen, and pelvis to rule out metastatic disease as per NCCN guidelines. Rigid proctoscopy is performed to assess clinical features of the cancer including measurement of the precise distance from the anal verge. Locoregional staging evaluation is performed with MRI using a rectal cancer staging protocol, unless MRI is medically contrain­dicated. Per NAPRC guidelines, endorectal ultrasound is considered an inferior stag­ing option, due to the lack of reproducibility and inability to serially assess radial margins in a multidisciplinary fashion. [4] Based on the assessment, decision is ren­dered to proceed with neoadjuvant therapy followed by surgical resection versus immediate surgical resection. Each rectal cancer case should be presented for con­sensus recommendations in the setting of a multidisciplinary tumor conference.
Managing perioperative risks are essential. All diabetic patients must have good perioperative glucose management, as reected by a preoperative Hba1c level. If ele­vated (>7.5%), aggressive comanagement with their endocrinologist is recommended. Additional modiable risk factors such as tobacco and alcohol use should be addressed with a cessation program in the allotted time period prior to the resection. Nutritional optimization should also be addressed and maximized, and obese patients are encour­aged to lose excess weight. Preoperatively, all patients undergo oral antibiotics and mechanical bowel preparation, as well as a standardized enhanced recovery protocol that includes multimodal pain regimen, early feeding, goal-directed uid therapy to minimize IV uids, and early mobilization. For additional details, please refer to Chaps. 7 and 8 on enhanced recovery protocols in colorectal surgery.
Although we do not routinely utilize ureteral stents, consideration of placement is important in cases that involve difcult pelvic anatomy such as a redo pelvic sur­gery or selected patients with T4 disease or history of perforated tumor. Lastly, if an ileostomy is planned (i.e., when performing a low pelvic anastomosis within 5cm from the anal verge or following neoadjuvant radiation or in the setting of malnutri­tion or immunosuppression), patients should meet with a wound ostomy nurse pre­operatively for education and stoma marking.
Monitor
23 Laparoscopic Low Anterior Resection forRectal Cancer: TME Planes andSurgery…
357
Room Setup andPatient Positioning
The most common laparoscopic approach is multiport surgery with the placement of four or ve ports. Reduced port techniques are feasible and included below. Single-port laparoscopic surgery can be performed, but anatomical constraints of the lower pelvic anatomy result in less-than-ideal exposure and access with this approach. Another approach, which can be especially useful is the morbidly obese, is a hand-assisted technique via either a Pfannenstiel or lower midline approach. The patient is secured to safely enable steep Trendelenburg and left­side elevation throughout the procedure. This should be ensured by a preoperative “Trendelenburg test.”
Intraoperative Positioning (Fig.23.1)
• Both arms tucked
• Modied lithotomy or split leg
• 5 (or 10) mm camera port at umbilicus
• 5mm ports in right upper quadrant (RUQ) and right lower quadrant (RLQ)
• Optional 5mm port in left lower quadrant (LLQ) or subxiphoid
Assistant
Surgeon
Fig. 23.1 Surgeon and room setup
Monitor
Surgical
tech
Back table